SCHEMBL29326288

SCHEMBL29326288

O=c1[nH]c2cc(-c3ccc4ccccc4c3)ccc2c(=O)n1-c1cccc2ccccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.49
NPEPPS P55786 2/20 0.48
FEN1 P39748 1/20 0.47
KDM4E B2RXH2 2/20 0.44
HTT P42858 1/20 0.44
PKM P14618 1/20 0.44
HSD17B10 Q99714 1/20 0.44
GAA P10253 2/20 0.43
PTGES O14684 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
LMNA P02545 1/20 0.40
PIM1 P11309 1/20 0.40
TP53 P04637 1/20 0.40
ADORA3 P0DMS8 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
ADORA1 P30542 1/20 0.38
CYP1A1 P04798 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29326223 0.91 FEN1 (0.58) TDP1NPEPPSFEN1KDM4EHTT
SCHEMBL29326224 0.88 NPEPPS (0.48) TDP1NPEPPSFEN1KDM4EHTT
SCHEMBL29326295 0.87 KDM4E (0.50) TDP1NPEPPSFEN1KDM4EHTT
SCHEMBL29326300 0.87 KDM4E (0.55) TDP1NPEPPSFEN1KDM4EHTT
SCHEMBL27377852 0.86 NPEPPS (0.44) NPEPPSFEN1KDM4EHTTPKM
SCHEMBL29326284 0.85 NPEPPS (0.42) TDP1NPEPPSFEN1KDM4EHTT
SCHEMBL29326233 0.85 FEN1 (0.45) TDP1NPEPPSFEN1KDM4EHTT
SCHEMBL29326437 0.84 KDM4E (0.50) TDP1NPEPPSFEN1KDM4EHTT
SCHEMBL29326225 0.84 NPEPPS (0.48) TDP1NPEPPSFEN1KDM4EHTT
SCHEMBL29326236 0.83 NPEPPS (0.44) TDP1NPEPPSFEN1KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239807-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239807-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE TDP1 2732/4885NPEPPS 168/4885FEN1 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.